Factors Associated With the Improved Survival of Head and Neck Neuroblastomas Compared to Other Body Sites. (March 2019)

• Record Type: Journal Article
• Authors: Kaufmann, Matthew R.; Camilon, P. Ryan; Janz, Tyler A.; Levi, Jessica R.
• Is Part Of: Annals of otology, rhinology & laryngology. Volume 128:Number 3(2019)
• Page Start: 241
• Page End: 248
• Publication Date: 2019-03
• Subjects: head and neck neoplasms -- miscellaneous -- outcome studies -- overall survival -- pediatric otolaryngology -- treatment of head and neck tumors; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1177/0003489418818586
• Languages: English
• ISSNs: 0003-4894

Abstract

Objective: To examine pediatric neuroblastoma survival and management in the head and neck compared to other body sites. Study Design: Retrospective analysis of a large population database. Methods: Patients in the Surveillance, Epidemiology, and End Results (SEER) database with neuroblastoma, NOS; ganglioneuroblastoma; or olfactory neuroblastoma diagnosed from birth to 18 years between 1973 and 2014 were included. These patients were classified into 1 of 3 categories based on primary tumor site: head and neck, adrenal, and "other." Results: Four thousand five hundred neuroblastoma cases were identified. One hundred seventy-five (3.9%) occurred in the head and neck, 1, 934 (43.0%) occurred in the adrenal gland, and 2, 391 (53.1%) occurred in "other" sites. The mean age at diagnosis was 4.21 years in the head and neck, 2.23 years in the adrenal gland, and 2.47 years in the "other" cohorts ( P < .001). Two- and 5-year disease-specific survival rates were 89% and 84% in the head and neck versus 77% and 65% in the adrenal and 84% and 77% in the "other" cohorts ( P < .001). The risk of disease-specific death (DSD) was higher in the adrenal cohort (adjusted hazard ratio [aHR] = 2.85; 95% CI, 1.54-5.27) compared to the head and neck cohort. Patients treated with surgery only had the lowest risk of DSD (aHR = 0.22; 95% CI, 0.13-0.35) compared to all other studied treatments. Conclusion: Our results demonstrate that primary neuroblastoma of the head and neck has a better prognosis than primary neuroblastoma of the adrenal gland.